Quidel Corp (QDEL) Tops Q3 EPS by 10c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Quidel Reports Third Quarter 2018 Financial Results
November 6, 2018 4:10 PM ESTSAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the third quarter ended September30, 2018.
Third Quarter 2018 Highlights
Total revenue was $117.4 million as compared to $50.9 million in the third quarter of 2017. Cardiac Immunoassay revenue was $65.3 million. Influenza revenue was $21.6 million as compared to $23.1 million in the third quarter of 2017. Reported GAAP EPS of$0.27 per diluted... More